Hot Takes: What the Oral Arguments in Hikma v. Amarin Revealed

Supreme Court heard oral arguments in Hikma Pharmaceuticals USA v. Amarin Pharma concerning generic drug "skinny labeling" and induced patent infringement standards. Justices appeared skeptical of creating new inducement rules, expressing concern about harming the generic pharmaceutical industry following the Federal Circuit's 2024 decision. The case involves whether Hikma's marketing statements for its generic Vascepa product actively induce infringement of Amarin's cardiovascular patents, with broad implications for Hatch-Waxman Act balance and generic drug accessibility.